ERBB3 EXPRESSION ASSESSED BY IMMUNOHISTOCHEMISTRY (IHC) IN NON-SMALL CELL LUNG CANCER (NSCLC) TUMORS WITH EGFR MUTATION, BEFORE EGFR-TYROSINE-KINASE INHIBITOR (EGFR-TKI) EXPOSURE

被引：0
|
作者：
Felip, Enriqueta [1 ]
Hernandez-Losa, Javier [2 ]
Murtra-Garrell, Nuria [1 ]
Freixinos, Victor [1 ]
Salcedo, Maite [2 ]
Tallada, Natalia [2 ]
Teixido, Cristina [2 ]
Martinez, Pablo [1 ]
Cedres, Susana [1 ]
Lopez, Eva [3 ]
Pandielle, Anastasio
Cajal, Santiago Ramon Y. [2 ]
机构：
[1] Vall Hebron Univ Hosp, Dept Oncol, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain
[3] Vall Hebron Hosp, Dept Stat, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
EGFR mutation; ErbB3;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1104 / S1105
页数：2
相关论文
共 50 条
  • [1] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [2] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [3] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitor (TKI)
    Sun, Jong-Mu
    Park, Min Jae
    Yi, Jun Ho
    Kong, Jeehyun
    Kim, Jung-A
    Lee, Soohyeon
    Yun, Lin A.
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S716 - S716
  • [5] Evaluation of EGFR degradation as a mechanism of tumor evasion in EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells compared to EGFR-TKI sensitive cells
    Norma, Hernandez-Pedro Y.
    Giovanny, Soca-Chafre
    Mario, Orozco-Morales
    Pedro, Barrios-Bernal
    Oscar, Arrieta
    CANCER RESEARCH, 2018, 78 (13)
  • [6] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [7] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [8] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [10] Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
    Ma, Shiqi
    Zhang, Lu
    Ren, Yuan
    Dai, Wei
    Chen, Tingqing
    Luo, Liping
    Zeng, Juan
    Mi, Kun
    Lang, Jinyi
    Cao, Bangrong
    ONCOGENE, 2021, 40 (14) : 2596 - 2609
12345